Iyintoni iHemorrhagic Cystitis?

I-cystitis ye-Hemorrhagic ukuvuvukala kwesibindi esenza intlungu kunye ne-hematuria, okanye igazi kumchamo. Kukho izizathu ezibangela ukuba umntu one- leukemia okanye i-lymphoma asemngciphekweni wokuphucula i-cystitis.

Izizathu

Iklasi eqhelekileyo ye-chemotherapy agents eyenza i-cystitis ephazamisayo yi-agents e-alkylating, i-cyclophosphamide kunye ne-ifamidide.

Ezi zezidakamizwa eziqhelekileyo ezisetyenziselwa unyango lwegazi kunye nomdlavuza wemrola, njenge-leukemia kunye ne-lymphoma. Ezinye ii-agent eziqhelekileyo ziquka i-temozolamide, i-bleomycin kunye ne-doxorubicin. I-hemorrhagic cystitis inokunye nezinye izizathu, kungekhona ngenxa yee-agent ezithintela ukunyanga komhlaza.

Xa umzimba uqhekeza i-cyclophosphamide okanye i-ifum, i-acrolein iveliswa, ehlanjululwayo egazini ngeentso kwaye iqhutywe kakhulu emcinini ngaphakathi kwesikhumba. Oku kuyacaphukisa umgca we-bladder, ekhokelela ekungathandeki kwe-cystitis kwakunye nezilonda ezingabangela ukuphuma kwegazi. Isiganeko se-cystitis esiyingozi kakhulu malunga neepesenti ezithandathu kubantu abaphantsi kokutsalwa kwethambo lomnxeba kunye nokufumana i-high-dose cyclophosphamide. Ifosphamide iye yadibana neemeko eziphezulu ze-cystitis kwezinye izifundo.

Ezinye iintsholongwane , ezifana ne-adenovirus, intsholongwane ye-BK, kunye ne-JC virus, nazo zingabangela i-cystitis eyingozi.

Abantu abanesistim somzimba esinciphileyo basengozini ephezulu yale miqathango, ingakumbi abo bahlaselwa emnxeni wethambo okanye ukutshintshwa kwe-cell stem .

Ekugqibeleni, ukucaphuka kwe-vestile kwi- exposure to radiation therapy kwakhona kubangelwa i-cystitis ephazamisayo kwizigulane zomhlaza.

Iimpawu

Ukuba uke wabuya uhlaselwe yintsholongwane enkulu yokuthintela umchamo, unalo uluvo lwezinye zeempawu ze-cystitis.

Ezi zimpawu ziquka:

Unokuba nezinye iimpawu ezifana nokukhathala kwi-anemia, okanye intlungu engacacanga kwisisu esezantsi, ngaphaya kwendawo ye-pubic yesifo se-pelvic.

Izinto zobungozi

Kukho izizathu ezimbalwa zokuba kutheni abantu abane-leukemia okanye i-lymphoma bangakwazi ukufumana i-cystitis ephazamisayo. Ezi zinto zibeka ingozi:

Unyango

I-hemorrhagic cystitis ingakhokelela ekulahlekelweni kwegazi kwaye ithathwa kakhulu. Izilonda ezivulekileyo kwi-bladder zinganika i-portal ibhaktheriya ukuba idlule kwigazi lakho. Kwakhona kunokukhokelela ekubanjeni ngokusisigxina kwebhanki, okungabangela ukucinywa kwephepha lomchamo okanye ukunyanzeliswa kwesisu. Ngoko ke, unyango olukhawulezayo le meko luyimfuneko.

Unyango lu no kuquka:

Thintelo

Indlela eyona ndlela yokunyanga i-cystitis eyingozi kukukhusela ukuba kwenzeke kwindawo yokuqala. Ukuba uchongiwe njengomngcipheko ophezulu wokuphuhlisa le nkxalabo, iqela lakho lezempilo liya kuthatha amanyathelo amanyathelo okuthintela. Uninzi lwongenelelo lusebenza ngokunciphisa inani lexesha apho ubhedu bhakeni lwakho luvezwa kwi-acrolein okanye kwezinye izinto ezivuthayo.

Ba no:

Nini ukuthetha noDokotela wakho

Kufanele udibanise neqela lakho lononophelo lwempilo ukuba:

Okukwintsusa

I-hemorrhagic cystitis yimeko enokubangela ukuba umonakalo omkhulu wegazi kunye nokuhlala unobungozi obungapheliyo xa ungaphathwa. Kukho izinto ezininzi ezibeka i-leukemia kunye nezigulane ze-lymphoma engozini yokwanda kwe-cystitis. Ngethamsanqa, kukho iindlela zokuncedisa le meko ukuba ingabikho, kwakunye neendlela zokuyiphatha xa kwenzeka.

Njengaye nawuphi na uphawu oluxakekayo, kufuneka uthethe nomboneleli wakho wezempilo ukuba unenkxalabo malunga nendlela owela ngayo umchamo wakho.

> Imithombo:

> MESNA Iphakheji Faka. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/20-855_Mesnex_Prntlbl.pdf. Kufike ngoJulayi 2017.

> I-Oncology: Indlela eSebenzisiweyo; UAlfred E. Chang, uPatricia A Ganz, uDaniel F. Hayes, uTimothy Kinsella, uHarvey I. Pass, uJoan H. Schiller, uRichard M. Stone, uVictor Strecher. I-Springer yeSayensi kunye neMedia Media, ngo-Dec 8, 2007.

> Riachy E, Krauel L, Rich Rich, et al. Imiba yengozi kunye nokuqikelela kwinqanaba eliqinileyo kunye neengxaki ze-cystitis ezinomntwana. J Urol . 2014; 191 (1): 186-92.